News Pharma Industry

dr lal pathlabs: Shaken, not stirred: Dr Lal PathLabs, Metropolis, et al. feel the heat of aggressive startups


Heightened competition and disruptive price moves by health-tech startups are posing a serious challenge for legacy diagnostics players like Dr Lal PathLabs, Metropolis Healthcare, SRL Diagnostics, and Vijaya Diagnostic Centre. With consumer behaviour changing, competitive intensity rising, and Covid-19 cases ebbing, can legacy diagnostic chains maintain their strong financial performance?

Recently, a seven-year-old health-tech player rattled the decades-old diagnostics industry. The disruptor, Tata 1mg, whose revenue is only about a fifth of industry leader Dr Lal PathLabs, launched deep discounts on diagnostics tests to draw customers to its platform. Tata 1mg is offering some routine tests, including lipid profile, liver function, and thyroid profile for just INR100, probably the lowest price in the industry currently. Another

  • SAVE

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link